Tech Company Financing Transactions
Progentos Therapeutics Funding Round
Progentos Therapeutics secured a $65 million Series A funding round on 5/20/2024. Investors included Forbion Capital Partners, Alta Partners and Dolby Family Ventures.
Transaction Overview
Company Name
Announced On
5/20/2024
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series A
Investors
Proceeds Purpose
This funding will enable the company to advance its MS program through human proof of concept studies and expand its pipeline in additional degenerative diseases.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
200 Dexter Ave
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Undisclosed
Website
Email Address
Overview
Progentos is developing a new approach to treating multiple sclerosis that stimulates the body's natural repair mechanisms. The myelin sheath is generated by specialized cells called oligodendrocytes. Progentos aims to develop novel, first in class small-molecule therapeutics to activate oligodendrocyte progenitor cells to regenerate oligodendrocytes and thus replace myelin lost to MS.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Loose
Chief Marketing Officer
Dana Hilt
Chief Scientific Officer
Sanjay Magavi
Browse more venture capital transactions:
Prev: 5/20/2024: Overland AI venture capital transaction
Next: 5/20/2024: Behavio venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs